BioCorRx Inc. reported its financial results for the first quarter of 2026, revealing a net revenue of $214,539, a significant increase of 59% compared to $134,899 in the same period last year. This growth is attributed primarily to new distribution sales from Lucemyra, an FDA-approved medication for opioid withdrawal, which has been integrated into the company's treatment offerings. The company also noted that sales/access fees rose to $1,330 from zero, reflecting an increase in the number of patients treated at licensed clinics.
Despite the revenue growth, BioCorRx experienced a net loss of $859,892 for the quarter, slightly higher than the loss of $851,764 reported in the first quarter of 2025. Total operating expenses increased to $1,170,539 from $1,072,845, driven by a rise in research and development costs, which surged to $352,333 from $161,919. The company also incurred $775,453 in selling, general, and administrative expenses, down from $886,083 in the prior year, indicating some cost management efforts.
In terms of operational developments, BioCorRx's cash position improved, ending the quarter with $211,911, up from $139,360 at the end of 2025. The company reported a working capital deficit of $7,506,752, raising concerns about its ability to continue as a going concern. The company has relied on private placements and advances from related parties to fund its operations, with $500,000 raised through a common stock subscription agreement during the quarter.
Strategically, BioCorRx has made significant moves, including acquiring an additional 12.15% ownership interest in its subsidiary, BioCorRx Pharmaceuticals Inc., through stock exchange agreements with related parties. This acquisition was part of a broader reorganization plan aimed at consolidating control over its pharmaceutical development efforts. The company is also actively pursuing FDA approval for its BICX104 implantable naltrexone product, which is supported by a recent grant of $11,029,977 from the National Institutes of Health for ongoing research.
Looking ahead, BioCorRx acknowledges the challenges it faces, particularly in securing additional capital to sustain operations and fund its development activities. The company is exploring various financing options but has expressed uncertainty regarding the availability and terms of such funding. As it navigates these challenges, BioCorRx remains focused on advancing its treatment programs and achieving regulatory milestones for its pharmaceutical products.
About BioCorRx Inc.
BioCorRx Inc. develops and provides addiction treatment solutions focused on substance use disorders, including alcoholism and opioid addiction. Its core offerings include the BioCorRx® Recovery Program, combining cognitive behavioral therapy and medication-assisted treatment, and the UnCraveRx® Weight Loss Program. Through its subsidiary BioCorRx Pharmaceuticals, the company develops implantable naltrexone pellets for long-acting treatment. It serves healthcare providers and patients, leveraging proprietary therapies and pharmaceutical innovations in addiction and weight management.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.